DOL Engagement · SolveLetter #5

Best Practices for Engaging HCP DOLs Through Evidence-Based Content

YP
Yakov Pakhomov, MD, PhD
December 2025 4 min read

One of the newer (and very real) headaches for Medical Affairs and Marketing teams is how to build a manageable system of scientific influence in digital channels. How do you work effectively with DOLs (Digital Opinion Leaders), the people shaping the professional conversation in social media, communities, and specialist chats?

For this to work at scale, you need content that is:

  • regular and consistent
  • genuinely meaningful (not “noise”)
  • insight-driven
  • practical for real clinical work

And it also needs to:

  • move through internal MLR/compliance smoothly
  • be tailored to each DOL’s profile, focus, and audience
  • be ready fast enough to stay ahead of the conversation

There’s a lot to do, and teams aren’t getting bigger. AI helps, but it still needs medical and compliance oversight. It’s not easy, but it’s solvable.

Below I briefly outline the key trends we see in DOL strategies, then describe how our continuous scientific content engine works: the Evidence Scanner Content Module. This is the system that has made this workload far more manageable for teams we’ve supported.

Trend #1. Niche DOLs often outperform “star” KOLs

It’s no longer enough to partner with a small group of top experts. Influence has become more specialised and more distributed.

A high-profile KOL is still valuable, but their agenda is broad and their time is limited. DOLs are often practicing physician-experts with deep niche expertise and a focused audience that cares most about real-world usability.

That’s why DOLs tend to:

  • unpack clinical scenarios
  • translate fresh evidence into practical decisions
  • answer the question peers care about most: “How do I use this tomorrow?”

HCPs consistently trust people who:

  • explain clearly
  • stay anchored in evidence
  • acknowledge limitations honestly
  • sound like a colleague from the real world, not a podium

What this means for pharma: you need to build relationships with more experts, and you need content that is more specific, more usable, and easier to tailor.

Trend #2. Platform shifts and higher risk: misinformation, brand safety, and pharmacovigilance

Platforms change, communities migrate, and discussions spread across many smaller spaces. At the same time, community formats are growing: groups, threads, and AMA sessions (Ask Me Anything).

In practice, one topic now lives in multiple places:

  • public social platforms
  • professional communities
  • private chats
  • niche forums

Risk is rising because:

  • conversations move faster than content can be reviewed and approved
  • speculation and inaccuracies appear more often
  • brands can end up next to content they would rather avoid (brand safety)
  • safety-relevant mentions may surface in unexpected channels (pharmacovigilance)

This is why having verified, ready-to-use scientific content available for DOLs has become so important.

Trend #3. Modular content that’s “MLR by design”

Long, generic decks are being replaced by a modular library of pre-approved building blocks. Teams can assemble the right format quickly for a specific DOL, channel, and moment.

Modules are updated continuously. New slides, short narratives, and interpretations are added regularly and approved in small batches as they appear.

Why this matters: review becomes faster, more predictable, and much easier to scale without losing consistency. And you deliver only what is directly relevant to each DOL — built from already vetted modules.

Trend #4. Pull formats beat push formats

Push means you publish on your schedule and hope the audience engages. Pull means you create access points where an HCP arrives when they need something: to request a resource, ask a question, choose a topic, or watch an expert breakdown.

Pull is especially effective with DOLs: they want credible materials on demand, not content delivered on the brand’s schedule.

Evidence Scanner Content Module: what the system does

1) Scans the science for your priority topics. It continuously monitors the sources that matter for Medical Affairs: PubMed, congress updates, clinical guidelines, and major reviews. The scan is built around practical “questions from the field,” not just keywords.

2) Turns evidence into decision-ready insights. Findings are grouped around clinical questions, with a focus on:

  • what may change practice
  • where the evidence is moving
  • what is most relevant for DOLs and HCPs
  • signals that may support RWE planning and medical strategy

3) Runs through medical and compliance validation. Medical reviewers check the interpretation and language, then align the output with local requirements and internal standards.

4) Delivers validated content in simple formats. Using templates, the module produces:

  • short summaries (1–2 pages)
  • slide sets
  • simple visuals and charts
  • key takeaways cards
  • email and messenger copy
  • scripts for short videos or podcasts

5) Operates on a predictable cadence. Monthly or quarterly updates make it easy to see what’s new for each key topic, without reinventing the workflow every time.

What this enables for Medical Affairs and Marketing

The Evidence Scanner Content Module helps you:

  • catch emerging topics early, before they become “hot” in DOL conversations
  • keep one consistent scientific story across channels (one process + one medical review)
  • work in a modular way (templates + insight packs assembled per DOL and channel)
  • support pull formats with credible scientific updates people actually want
  • reduce compliance risk and speed up MSL/Medical Advisor responses with validated, reusable content

How are you working with DOLs today? If you’d like to compare approaches, I’m always happy to talk — or request examples of the module’s output.

Newsletter
Get SolveLetter monthly in your inbox
Evidence strategy, advisory board insights, AI tools, and regulatory updates — curated for pharma medical affairs teams.
1–2 articles per month, never more
Practical insights from real projects
Free forever, unsubscribe anytime
Subscribe to SolveLetter
Join 1,200+ pharma professionals. No spam.
Evidence Scanner
Evidence ScannerTM
AI infrastructure

AI-powered.
Expert-validated.

We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.

Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Advisory board transcription + structured AI summary
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
Evidence Scanner · Monitoring module
// Weekly digest: GLP-1 RA publications
monitor("GLP-1 receptor agonist", {
  frequency: "weekly",
  sources: ["pubmed", "congress_abstracts"]
})
Scanning 12 sources...
Weekly Digest · Feb 24–Mar 2
7 new publications found. 2 RCTs, 3 RWE studies, 2 meta-analyses. Key finding: MACE benefit confirmed in CVOT pooled analysis...